Venetoclax for AML

(4:3)

Venetoclax for AML

(2:25)

Managing Venetoclax for CLL

(3:46)

Venetoclax For Myeloma | Therapies on the Horizon #myeloma

(13:40)

Venetoclax for patients with chronic lymphocytic leukaemia \u0026 small lymphocytic lymphoma

(9:15)

Ibrutinib + Venetoclax for CLL

(3:1econd)

Ponatinib plus venetoclax for R/R Ph+ ALL

(3:16)

Achieving undetectable MRD with ibrutinib plus venetoclax for CLL

(1:53)

The addition of pegfilgrastim to reduce the toxicity of CLIA plus venetoclax in patients with AML

(3:6)

Venetoclax for multiple myeloma - mechanism of action and next steps

(1:58)

Zanubrutinib plus venetoclax for patients with CLL

(1:3)

Update on Venetoclax for CLL

(24:9)

Obinutuzumab + Venetoclax for Frontline CLL

(9:15)

Toxicity Management With Venetoclax for CLL

(7:9)

Venetoclax for Enhancing Immune Function in CLL and Multiomic Evaluation With Dr. Matthew Cortese

(15:19)

Update on venetoclax for CLL: How low can you go (MRD)?

(21:50)

Updates from CAPTIVATE: ibrutinib and venetoclax for CLL

(5:54)

Ibrutinib plus venetoclax for first-line treatment of CLL: 4-year follow-up data

(1:56)

Safety analysis of the BCL-2 inhibitor venetoclax for CLL

(1:6)

Venetoclax for elderly AML patients

(55)